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A B S T R A C T   
Cerebrospinal fluid (CSF) enhancement on T2-weighted post-contrast fluid-attenuated inversion recovery 
(pcT2wFLAIR) images is a relatively unknown neuroradiological marker for gadolinium-based contrast agent 
extravasation due to blood–brain barrier (BBB) disruption. We systematically reviewed human studies reporting 
on CSF enhancement on pcT2wFLAIR images to provide a comprehensive overview of prevalence of this new 
biomarker in healthy and diseased populations as well as its etiology and optimal detection methodology. We 
extracted information on the prevalence of CSF enhancement, its vascular risk factor and neuroimaging corre-
lates, and methodological attributes of each study. Forty-four eligible studies were identified. By pooling data, we 
found that the prevalence of CSF enhancement was 82% (95% confidence interval (CI) 80–89) in meningitis (4 
studies, 65 patients), 73% (95%CI 62–81) in cases with (post-) acute intracerebral hemorrhage (2 studies, 77 
cases), 64% (95% CI 54–73) in cases who underwent surgery for aneurysm treatment (2 studies, 99 patients), 
40% (95% CI 30–51) in cases who underwent surgery for carotid artery disease treatment (3 studies, 76 patients), 
27% (95% CI 25–30) in cases with acute ischemic stroke (9 studies, 1148 patients), 21% (95% CI 17–23) in 
multiple sclerosis (6 studies, 897 patients), and 13% (95% CI 7–21) in adult controls (4 studies, 112 cases). 
Presence of CSF enhancement was associated with higher age in eleven studies, with lobar cerebral microbleeds 
in one study, and with cerebral atrophy in four studies. PcT2wFLAIR imaging represents a promising method that 
can provide novel perspectives on BBB leakage into CSF compartments, with the potential to reveal important 
new insights into the pathophysiological mechanisms of varying neurological diseases.   
1. Introduction background 
Bood-brain barrier (BBB) disruption plays a pivotal role in the 
pathophysiology of many neurological diseases (Starr, 2003; Cramer 
et al., 2015; Villringer, 2017). Disruption of the BBB can be assessed in 
living individuals in the form of gadolinium-based contrast agent 
(GBCA) leakage with contrast-enhanced magnetic resonance imaging 
(MRI). A novel and relatively unknown neuroradiological marker for 
GBCA extravasation due to presumed BBB (or blood-cerebrospinal fluid 
barrier) disruption is cerebrospinal fluid (CSF) enhancement on post- 
contrast (pc) T2-weighted fluid-attenuated inversion recovery 
(T2wFLAIR) images (box 1). The FLAIR signal hyperintensity following 
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contrast administration becomes visible because the CSF is no longer 
fully suppressed by the inversion pulse due to local shortening of the T1- 
relaxation time caused by GBCA leakage into the CSF. PcT2wFLAIR has 
several important differences compared to pcT1-weighted (T1w) MRI, 
which currently is the most widely-used and conventional method for 
the assessment of BBB leakage (box 2) (Raja et al., 2018; Thrippleton, 
2019). Because of its unique properties, pcT2wFLAIR imaging 
represents a promising method to gain novel insights into the dynamics 
and extent of BBB leakage and CSF-clearance mechanisms in aging and 
neurological diseases. 
Although first published reports of pcT2wFLAIR CSF enhancement 
date back to the late 90′s (Lev and Schaefer, 1999; Mathews, 1999), only 
few studies have been published on this topic ever since. In contrast, 
since the first GBCAs became available for clinical use globally during 
Box 1 
: Definitions of terminology used throughout the paper 
Blood-brain barrier (BBB) disruption: Extravasation of blood constituents (including gadolinium-based contrast agents (GBCAs)) into the 
brain tissue and surrouning fluid-filled spaces. 
CSF enhancement: The radiologic finding of hyperintense signal within the cerebrospinal and/or interstitial fluid space, including the ven-
tricles, subarachnoid space and perivascular space, on post-contrast T2-weighted FLAIR images, presumably caused by GBCA extravasation due 
to BBB disruption.  
Fig. 1. Different appearances of post-contrast T2-weighted FLAIR cerebrospinal fluid enhancement. The top row shows pre- (A1) and post- (A2) contrast T2-weighted 
FLAIR images in a stroke patient. The post-contrast image was acquired approximately 24 h after contrast administration and within 48 h after stroke onset, and 
shows widespread sulcal hyperintensities [Reprinted with permission from Springer Nature, European Radiology; license number 4818791304726 (Ostwaldt, 2015). 
The bottom row shows pre- (B1) and post- (B2) contrast T2-weighted FLAIR images in a cognitively normal older individual (Freeze, 2017). The post-contrast image 
was acquired approximately 16 min after contrast administration and shows a focal punctate hyperintensity. All images were acquired at a field strangth of 3 T. Note 
that the difference in appearance can possibly be attributed to individual case characteristics, but also to the difference in post-contrast acquisition timing. 
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the late 80′s (Lohrke, 2016), a large number of studies were published on 
BBB leakage measured with pcT1-weighted imaging. A potential reason 
for this difference in popularity may simply be that most studies focus on 
the brain parenchyma, in which pcT1-weighted imaging is known to be 
more sensitive to detect GBCA leakage than pcT2wFLAIR. However, the 
number of studies using pcT2wFLAIR imaging has substantially 
increased in recent years, providing a new perspective on BBB leakage in 
healthy and diseased populations. 
Previous studies have applied pcT2wFLAIR to demonstrate GBCA 
leakage in the form of CSF enhancement in various neurological diseases 
with presumed BBB disruption, but also in non-diseased controls 
(Freeze, 2017; Absinta, 2017). The appearance of these MRI signal ab-
normalities is highly variable and can range from very subtle single- 
focus or multi-focal pericortical signal enhancement in memory clinic 
patients, to more widespread enhancement in patients with acute 
ischemic stroke (Fig. 1). It is unclear how frequent this neuroradiolog-
ical phenomenon appears in different disease populations and there is 
currently no consensus regarding its terminology, definition and optimal 
detection methodology. Moreover, it is unknown whether pcT2wFLAIR 
CSF enhancement is associated with common vascular risk factors, 
neuroradiological imaging markers of vascular and neurodegenerative 
disease, or a poor prognosis. In this systematic review we aimed to 
provide a comprehensive overview of published studies on pcT2wFLAIR 
CSF enhancement. 
2. Methods 
2.1. Literature search strategy 
We identified studies through a systematic search of MEDLINE 
(1946-January 29, 2020) and EMBASE (1974-January 29, 2020) (ap-
pendix e-1). We followed the PRISMA guideline (Preferred Reporting 
Items for Systematic Reviews and Meta-Analyses). 
2.2. Inclusion and exclusion criteria 
We included human in vivo MRI-studies of the brain in which a 
T2wFLAIR sequence was performed after administration of a GBCA with 
visual assessment of leakage (signal enhancement) within the CSF space 
(including the subarachnoid space, ventricles, and perivascular spaces). 
We excluded conference reports, comments, case reports (defined as 
n < 5 cases), reviews, and articles in languages other than English. We 
excluded studies that assessed enhancement on T1wFLAIR images, 
studies that applied contrast administration intrathecally, studies that 
only included participants < 18 years old, studies that assessed ocular 
enhancement, and studies that examined enhancement surrounding 
circumventricular organs (structures lining the cavity of the third and 
fourth ventricle, which facilitate communication between the central 
nervous system and peripheral blood; these structures do not have a 
BBB). In addition, we excluded studies in cases with tumors because the 
blood-tumor barrier is known to have distinct features compared to the 
BBB (including increased permeability) (Arvanitis et al., 2020). If a 
study included both cases with tumors as well as cases eligible for in-
clusion in our review, we included the study if extraction of data was 
possible for eligible cases separately. 
2.3. Selection of studies 
Title and abstract screening to select studies that were potentially 
eligible for inclusion was performed in duplicate by two independent 
authors (W.M.F. and M.vd.T.), who subsequently reviewed full-text 
versions of these studies. One case of uncertainty with regard to ab-
stract and full-text screening was discussed with a third author (S.J.v. 
V.). The reference lists of the included articles were screened for addi-
tional papers. Two studies reported findings from exactly the same 
ischemic stroke case series (duplicate dataset), and therefore we pooled 
the results of these studies for the purpose of this review (Warach and 
Latour, 2004; Latour et al., 2004). 
2.4. Study quality assessment 
We assessed the methodological quality of the studies based on a 
version of the Newcastle Ottawa Scale that was adapted for case series 
studies (Herzog, 2013; Wells, 2017). In addition, we critically appraised 
the literature by discussing potential bias in the individual studies. 
2.5. Data extraction 
Data were extracted from the included studies using a prespecified 
and piloted data file by two independent authors (W.M.F. and M.vd.T). 
Discrepancies were resolved in consensus between these authors. The 
primary outcome variable of interest was the prevalence of pcT2wFLAIR 
CSF enhancement in each study sample. In addition, we extracted the 
following data: (1) details on the study sample (disease type, mean/ 
median age, % female) and study design (cross-sectional/longitudinal 
and retrospective/prospective), (2) definition/terminology and loca-
tion/appearance of pcT2wFLAIR CSF enhancement, (3) MRI acquisition 
details, (4) reports of associations with possible (vascular) risk factors 
(including age, sex, hypertension, diabetes mellitus, hyperlipidemia, 
and smoking) and conventional vascular and neurodegenerative neu-
roimaging markers (including white matter hyperintensities (WMH), 
lacunar infarcts, cerebral microbleeds and cerebral atrophy), and (5) 
assessment of a clinical outcome variable at least 1 month after pre-
sentation with pcT2wFLAIR CSF enhancement (to assess the prognostic 
value of CSF enhancement). 
2.6. Data analysis 
Because prevalence of pcT2wFLAIR CSF enhancement was the pri-
mary outcome variable of interest, we computed pooled prevalence es-
timates for broadly comparable disease groups when possible. When 
computing the pooled prevalence estimates, we only included individual 
studies that did not select their study sample based on CSF enhancement 
positivity (i.e., non-selective studies). When there was known or 
Box 2 
: Important differences between pcT2wFLAIR and pcT1w imaging.  
• pcT2wFLAIR imaging is more suitable for the detection of subtle GBCA leakage into the CSF compared to pcT1w imaging, with up to 10 times 
higher sensitivity at low CSF gadolinium concentrations (Freeze, 2017; Kohrmann et al., 2012).  
• in contrast to pcT1wMRI, pcT2wFLAIR imaging is relatively insensitive to GBCA leakage into the brain parenchyma, which can be attributed 
to its T2-weighted component (Freeze, 2017; Mamourian et al., 2000).  
• pcT2wFLAIR is insensitive to high GBCA concentrations in blood vessels, and as such allows for the ‘pure’ detection of BBB leakage of GBCA in 
the CSF without interference from high signal due to high GBCA concentrations in leptomeningeal blood vessels that is typically observed on 
pcT1w imaging.  
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suspected overlap between study samples, we included the study with 
the largest study sample in the pooled data presentation (i.e., non- 
overlapping studies). We calculated the prevalence of CSF enhance-
ment by dividing the number of cases with CSF enhancement by the total 
number of study participants. We obtained 95% confidence intervals 
(95% CI) using the modified Wald method with the DescTool package in 
R statistical software (R version 3.6.1) (Agresti and Coull, 1998; R Core 
Team. R: A, 2016). In addition, we computed the pooled mean age for 
each disease group by taking the sum of the mean age (if not available, 
the median was taken instead) * number of participants of each study 
divided by the total number of study participants. 
3. Results 
Forty-four out of 388 unique publications met the inclusion criteria 
(Fig. 2). Most studies were performed in cases with ischemic stroke, 
transient ischemic attack (TIA), and/or intracerebral hemorrhage (ICH) 
(n = 20) (Villringer, 2017; Ostwaldt, 2015, 2014; Warach and Latour, 
2004; Latour et al., 2004; Choi, 2017; Dechambre, 2000; Forster et al., 
2016; Gupta, 2017; Henning et al., 2008; Hjort, 2008; Kim, 2005; Luby, 
2019; Nadareishvili, 2018; Lee, 2015, 2016, 2018; Rozanski, 2010; 
Kidwell et al., 2011; Jolink, et al., 2019; Barr, 2010). Six studies 
described patients who underwent cardiovascular or intracranial 
vascular surgery (Cho, 2014; Ogami et al., 2011; Wilkinson, 2000; Li, 
2018; Suthiphosuwan et al., 2018; Merino, 2013), nine studies patients 
with multiple sclerosis (MS) (one of these included stroke cases as a 
positive control (Eisele, 2015) (Eisele, 2015; Absinta, 2015; Bergsland, 
2019; Harrison, 2017; Jonas et al., 2018; Zivadinov, 2017, 2018; Zur-
awski, 2020; Ighani, 2020), four studies patients with meningitis 
(Ahmad et al., 2015; Alonso, 2015; Fukuoka, 2010; Splendiani, 2005), 
two studies reported on memory clinic patients and normal aging 
(Freeze, 2017, 2019), one study on Susac syndrome and MS (Coulette, 
2019), one study on familial amyloid polyneuropathy (Hirai, 2005), and 
one study included a mix of diseases, which were presented as follows: 
inflammatory and immune-mediated neurologic diseases (neuromyelitis 
optica spectrum disorder, immune-mediated encephalitis, immune- 
mediated cerebellar ataxia, systemic inflammatory diseases with white 
matter MRI abnormalities not suggestive for MS and Susac syndrome), 
noninflammatory neurologic diseases (small vessel disease, migraine, 
neurodegenerative diseases, compressive myelopathy), human T-lym-
photropic virus (HTLV) infection, and human immunodeficiency virus 
(HIV) infection (Absinta, 2017). 
3.1. Methodological quality of the individual studies 
The methodological quality of the studies as assessed with the 
adapted Newcastle-Ottawa scale (Herzog, 2013; Wells, 2017) varied 
from poor (score 3/8) to excellent (score 8/8) (details of the study 
quality assessment can be found in supplemental table e-1). The average 
quality score for studies in patients with stroke, post-cardiovascular and 
intracranial vascular surgery, and meningitis was moderate (score 5/8), 
while studies in patients with MS had a higher average quality score 
(score 7/8). 
Bias, confounding factors and chance should be considered when 
interpreting the results of the individual studies. Inherent to the nature 
of the method, all studies of pcT2wFLAIR enhancement were subject to 
selection bias because participants needed to be eligible for MRI and 
GBCA administration (patients that are typically excluded are those with 
cardiac pacemakers and renal failure). Apart from this, 23 studies 
included cases that were reasonably representative of their population 
Fig. 2. Flow chart of study selection.  
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Fig. 3. The prevalence of pcT2wFLAIR CSF enhancement across disease groups. Point estimates are represented by squares for individual studies, and diamonds for 
summed disease categories. The area of each point estimate is proportional to the size of each study. The error bars represent 95% confidence intervals. N = sample 
size, n = number of cases with pcT2wFLAIR CSF enhancement. * Study sample included both cases with ischemic stroke as well as cases with intracere-
bral hemorrhage. 
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(i.e. (semi-) consecutive case series or prospective cohort study), but 21 
studies used mostly retrospectively collected data with insufficient de-
tails on case selection procedures, and three of these selected only cases 
with CSF enhancement positivity (supplemental table e-1 and e-2). In 
addition, some studies did not mention that the assessment of CSF 
enhancement was performed while blinded to clinical data (20 studies). 
Confounding factors may have influenced the results within several 
studies, including failure to acquire pre-contrast FLAIR scans for all 
participants (15 studies), variable post-contrast image acquisition delay 
times (14 studies), and variable contrast agent dosage within the studied 
samples (11 studies) (supplemental table e-1 and e-5). Finally, results of 
studies with smaller sample sizes are more susceptible to chance (13 
studies included n < 30). 
3.2. Prevalence of CSF enhancement 
3.2.1. Stroke 
Twenty-one studies assessed CSF enhancement in cases with stroke 
(supplemental table e-2). Fourteen studies examined acute ischemic 
stroke, including nine studies with non-selective and non-overlapping 
study samples with a total of 1148 cases and a pooled mean age of 
70 years (Ostwaldt, 2015; Warach and Latour, 2004; Latour et al., 2004; 
Choi, 2017; Forster et al., 2016; Gupta, 2017; Hjort, 2008; Kim, 2005; 
Luby, 2019; Nadareishvili, 2018). The reported prevalence of CSF 
enhancement in these studies ranged from 12% to 65%, with a pooled 
prevalence estimate of 27% (95% CI 25–30). Four studies included a mix 
of cases with acute ischemic stroke and TIA, including two studies with 
non-overlapping study samples in 623 cases and a pooled mean age of 
60 years (Lee, 2015, 2018). These studies reported prevalence estimates 
of 12% and 4%, corresponding to a pooled prevalence estimate of 12% 
(95% CI 9–14) when combined. Two studies in a total of 77 cases with 
lobar or deep ICH and a pooled mean age of 63 years reported higher 
prevalence numbers of 54% (post-acute ICH) (Jolink, et al., 2019)and 
85% (acute ICH) (Kidwell et al., 2011), with a pooled prevalence esti-
mate of 73% (95% CI 62–81). One additional study included a mix of 41 
cases (mean age 62 years) with acute ischemic stroke, TIA, and ICH 
(Barr, 2010), and reported a prevalence of 41% (Fig. 3). 
3.2.2. Cardiovascular or intracranial surgery 
Six studies assessed CSF enhancement in the acute phase after car-
diovascular or intracranial vascular surgery (supplemental table e-2). 
Among these were three studies in a total of 76 cases with a pooled mean 
age of 70 years who underwent carotid stenting or carotid endarterec-
tomy in the context of carotid artery disease, which reported prevalence 
numbers of 18% (Cho, 2014); 54% (Ogami et al., 2011); and 100% 
(Wilkinson, 2000). When these studies were combined, the pooled 
prevalence estimate was 40% (95% CI 30–51). Two studies examined a 
total of 99 cases with a pooled mean age of 58 years who underwent 
unruptured aneurysm treatment and reported prevalence numbers of 
52% (Suthiphosuwan et al., 2018)and 83% (Li, 2018), with a combined 
prevalence estimate of 64% (95% CI 54–73). In addition, one study in 19 
cases (mean age 67 years) who underwent cardiac surgery reported a 
prevalence of 47% (Merino, 2013)(Fig. 3). 
3.2.3. Multiple sclerosis 
Nine studies assessed CSF enhancement in MS, of which six with non- 
overlapping study samples including 897 cases with a pooled mean age 
of 44 years (supplemental table e-2) (Zurawski, 2020; Ighani, 2020; 
Coulette, 2019; Eisele, 2015; Absinta, 2015; Bergsland, 2019). The re-
ported prevalence estimates within these studies ranged between 1% 
and 80%, with a pooled prevalence estimate of 21% (95% CI 19–24). 
Because of the wide variation in reported prevalence we inspected the 
extracted data and found that the wide variation seemed to be related to 
magnetic field strength differences between studies. Studies that used 
3 T MRI reported prevalence estimates between 1% and 25% (Eisele, 
2015; Bergsland, 2019; Coulette, 2019), while studies that used 7 T MRI 
report estimates of 67% (Zurawski, 2020)and 80% (Ighani, 2020). 
3.2.4. Meningitis 
Four studies in 65 cases with meningitis with mixed etiological 
causes (viral, bacterial, fungal) with a pooled mean age of 47 years re-
ported prevalence estimates between 50% and 100%, resulting in a 
pooled prevalence estimate of 82% (95% CI 70–89) (supplemental table 
e-2) (Ahmad et al., 2015; Alonso, 2015; Fukuoka, 2010; Splendiani, 
2005). 
3.2.5. Other diseases 
For several other diseases it was not possible to assess pooled prev-
alence estimates because only single or overlapping studies were found. 
Among these was one study in 48 memory clinic patients (mean age 
70 years) reporting a prevalence estimate of 33% (Freeze, 2017). One 
study in nine cases with Susac syndrome (mean age 38 years) reported a 
prevalence estimate of 56% (Coulette, 2019). Another study in familial 
amyloid polyneuropathy (mean age 40 years) found CSF enhancement 
in three out of six cases (50%) (Hirai, 2005). In addition, we included 
one study that reported a prevalence of 35% in a mixed group of 51 cases 
(mean age 43 years) with diagnoses of neuromyelitis optica spectrum 
disorder, immune-mediated encephalitis, immune-mediated cerebellar 
ataxia, systemic inflammatory diseases with white matter MRI abnor-
malities not suggestive for MS, and Susac syndrome, a prevalence of 8% 
in a group of 38 cases (mean age 50 years) with mixed noninflammatory 
neurologic diseases, including small vessel disease, migraine, neurode-
generative diseases, and compressive myelopathy, a prevalence of 45% 
in 38 cases with HTLV infection (mean age 53 years), and a prevalence 
of 21% among 61 cases with HIV infection (mean age 52 years) (sup-
plemental table e-2) (Absinta, 2017). 
3.2.6. Control cases 
Among seven studies that included control cases, four had non- 
overlapping study samples including a total of 112 cases (mean age 
50 years, supplemental table e-3) (Freeze, 2017; Absinta, 2017; Zur-
awski, 2020; Ighani, 2020). The reported prevalence numbers of CSF 
enhancement ranged between 7% and 60%, although the latter study 
included only five participants. The pooled prevalence estimate of the 
controls in all studies combined was 13% (95% CI 7–20) (Fig. 3). 
3.3. Terminology of CSF enhancement 
Most studies referred to pcT2wFLAIR CSF enhancement with either 
the term ‘HARM’ (hyperintense acute reperfusion marker) or the term 
‘LME’ (leptomeningeal enhancement) (supplemental table e-4). The 
term HARM was introduced in 2004 by Warach and Latour because they 
hypothesized that enhancement of the CSF space in acute ischemic 
stroke was related to reperfusion injury (Warach and Latour, 2004). 
Since then, many studies in acute ischemic stroke (Villringer, 2017; 
Ostwaldt, 2015, 2014; Choi, 2017; Forster et al., 2016; Gupta, 2017; 
Henning et al., 2008; Hjort, 2008; Luby, 2019; Nadareishvili, 2018; Lee, 
2015, 2016, 2018; Rozanski, 2010), but also studies in hemorrhagic 
stroke (Kidwell et al., 2011; Jolink, et al., 2019), treatment for carotid 
artery disease (Cho, 2014), and cardiac surgery (Merino, 2013), have 
adopted the term. By comparison, the term ‘LME’ refers to the abnormal 
accumulation of contrast media in the pia mater, arachnoid mater, and/ 
or the subarachnoid space, and has also been used by studies in a variety 
of diseases, including ischemic stroke (Wilkinson, 2000), MS (Absinta, 
2015; Harrison, 2017; Coulette, 2019a, 2019b; Zurawski, 2020; Ighani, 
2020; Ahmad et al., 2015; Alonso, 2015; Fukuoka, 2010; Splendiani, 
2005; Freeze, 2019), and meningitis (Ahmad et al., 2015; Alonso, 2015; 
Fukuoka, 2010). 
3.4. Definition of CSF enhancement 
All studies that mentioned a definition of CSF enhancement 
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acknowledged the appearance of contrast enhancement within the CSF 
(ventricles and/or sulci and/or cisterns) and/or leptomeninges (sub-
arachnoid space and/or leptomeningeal compartment) (supplemental 
table e-4). Some studies included also parenchymal hyperintensities in 
their definition (and these were also reported) (Gupta, 2017; Lee, 2016; 
Jolink, et al., 2019; Suthiphosuwan et al., 2018). Several studies defined 
that the CSF enhancement needed to be brighter than cortical tissue or a 
superficial cortical vein with visual assessment (Freeze, 2017, 2019; 
Absinta, 2017, 2015; Dechambre, 2000; Suthiphosuwan et al., 2018; 
Bergsland, 2019; Zivadinov, 2017, 2018; Coulette, 2019). Some studies 
required the CSF enhancement to be visible on multiple consecutive 
slices (Ostwaldt, 2015; Nadareishvili, 2018; Barr, 2010; Ahmad et al., 
2015). 
3.5. Appearance and location of CSF enhancement 
Manually drawn illustrative examples of the different appearance 
patterns of CSF enhancement are displayed in Fig. 4. 
3.5.1. Stroke 
Descriptions of the appearance of CSF enhancement in stroke studies 
ranged from focal to sulcal to diffuse (supplemental table e-4). 
Interestingly, some studies that examined CSF enhancement at multiple 
timepoints showed that enhancement was absent or focal within mi-
nutes after contrast administration, while diffuse enhancement was 
observed after multiple hours and up to five days after initial contrast 
administration (Warach and Latour, 2004; Latour et al., 2004; Lee, 
2015, 2016). Some studies reported a positive association between 
contrast agent dosage and CSF enhancement (Ostwaldt, 2015, 2014). 
Locations of CSF enhancement included sulci, subarachnoid space, 
ventricles, and cisterns. From studies in acute ischemic stroke it could be 
inferred that the enhancement was frequently observed in, but not 
necessarily restricted to, the same vascular territory and hemisphere as 
the infarction (Ostwaldt, 2015; Warach and Latour, 2004; Latour et al., 
2004; Henning et al., 2008; Kim, 2005; Luby, 2019; Lee, 2016; Choi, 
2017; Dechambre, 2000; Forster et al., 2016). In contrast, two studies in 
ICH reported that CSF enhancement was noncontiguous with the hem-
orrhage (Kidwell et al., 2011; Jolink, et al., 2019). 
3.5.2. Cardiovascular or intracranial surgery 
CSF enhancement was described as focal, sulcal, lobar or diffuse 
(supplemental table e-4) (Wilkinson, 2000; Li, 2018; Merino, 2013). 
PcT2wFLAIR scans were acquired shortly after contrast administration 
or after several hours, but none of the studies assessed the course of CSF 
Fig. 4. Schematic representation of different appearance patterns of CSF enhancement. A) Typical presentations of CSF enhancement within minutes after GBCA 
administration. These patterns were described in different diseases, including ischemic stroke, hemorrhagic stroke, carotid artery disease treatment, aneurysm 
treatment, cardiac surgery, multiple sclerosis, memory clinic patients, Susac syndrome (lesions were frequently observed in the posterior fossa). These types of CSF 
enhancement typically appear within minutes after GBCA administration. Meningitis was an exception to this: cases with meningitis typically display diffuse 
meningeal enhancement within minutes after GBCA administration on pcT2wFLAIR images. B) Typical presentations of CSF enhancement within hours to days after 
GBCA administration. Patterns like these were described in acute ischemic stroke, hemorrhagic stroke, treatment for carotid artery disease, aneurysm treatment, 
cardiac surgery, and familial amyloid polyneuropathy. Note: the CSF enhancement patterns were manually drawn on an example pre-contrast FLAIR image from our 
previous study (Villringer, 2017)using online photo editor software (www.pixlr.com).’ 
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enhancement over time. Two studies in patients that underwent treat-
ment for carotid artery disease described the enhancement as being 
primarily located within the territory of the middle cerebral artery 
(Ogami et al., 2011; Wilkinson, 2000). 
3.5.3. Multiple sclerosis 
CSF enhancement appeared as single or multiple foci in MS (sup-
plemental table e-4). All studies assessed CSF enhancement shortly (i.e., 
within 10–20 min) after contrast administration. Three studies used a 
subtraction method of pre- and post-contrast FLAIR scans to detect CSF 
enhancement (Harrison, 2017; Zivadinov, 2018; Ighani, 2020). The 
majority of foci were located supratentorially (Ighani, 2020; Coulette, 
2019; Jonas et al., 2018; Zivadinov, 2017, 2018). Two studies performed 
longitudinal imaging and found that the majority of foci (>82%) 
appeared stable over a time period of multiple years (Absinta, 2015; 
Jonas et al., 2018). 
3.5.4. Meningitis 
CSF enhancement in cases with meningitis was described as cir-
cumscribed or diffuse, either within the sulci along each cerebral lobe of 
both hemispheres and the cerebellum, or confined to the supratentorial 
leptomeninges (supplemental table e-4) (Alonso, 2015; Fukuoka, 2010; 
Splendiani, 2005). All studies assessed CSF enhancement within minutes 
after contrast administration. 
3.5.5. Control cases 
CSF enhancement in control cases was assessed within minutes after 
contrast administration and described as focal (supplemental table e-4) 
(Freeze, 2017, 2019; Absinta, 2017, 2015; Zurawski, 2020; Ighani, 
2020). On follow-up imaging after >1 year the foci remained stable 
(Freeze, 2017, 2019). 
3.6. MRI details 
The MRI acquisition details, contrast dosage, and contrast agent type 
were highly variable between studies (supplemental table e-5). The 
magnetic field strength ranged from 1.5 T (T) (n = 14 studies), a mix of 
1.5 T and 3 T (n = 6 studies), 3 T (n = 18 studies), to 7 T (n = 5 studies), 
and one study did not mention field strength (Lee, 2018). The FLAIR 
sequence parameters varied significantly, even between studies using 
the same magnetic field strength, which can possibly be attributed to 
manufacturer or site preferences. For example, the echo time of studies 
performed at 3 T ranged between 100 and 500 ms. Slice thickness 
ranged between 0.7 and 7.0 mm, where specified; 11 studies did not 
mention slice thickness. Contrast agent types that were used included 
gadobutrol (10 studies), gadopentetate (12 studies), gadoterate (4 
studies), gadobenate (2 studies), gadoteridol (3 studies), gadodiamide (1 
study), some studies used two different types of contrast agents on 
different cases (n = 2 studies), and 10 studies did not mention the 
contrast agent type. Contrast agent doses that were applied also varied, 
although most studies used a single dose (0.1 mmol/kg, n = 26 studies). 
One study applied a double dose (0.2 mmol/kg), two studies used a 
double dose or a fixed dose of 15 ml gadobutrol (which translates to a 
double dose for a 75 kg person; vial concentration, 1 mmol/ml), several 
studies reported a fixed dose (15 ml gadopentetate (0.5 mmol/ml); 
20 ml gadobenate (0.5 mmol/ml); 4–6 ml or 10 ml gadobutrol), six 
studies used variable or multiple contrast agent administrations, and 
five studies did not mention the dosage. Because of the large heteroge-
neity in study samples/diseases and MRI acquisition details we did not 
set out to explore associations between specific imaging parameters and 
prevalence of CSF enhancement. 
3.7. Risk factor and neuroradiological correlates 
Eleven out of 21 studies found that CSF enhancement increased with 
increasing age (supplemental table e-6) (Freeze, 2017; Ostwaldt, 2015; 
Warach and Latour, 2004; Latour et al., 2004; Lee, 2015; Rozanski, 
2010; Barr, 2010; Ogami et al., 2011; Absinta, 2015; Zivadinov, 2018). 
Studies that assessed sex (n = 19), hypertension (n = 12), diabetes 
mellitus (n = 10), hyperlipidemia (n = 6) or smoking (n = 6) as potential 
risk factors for CSF enhancement did not find any significant associa-
tions, except for two studies that found a negative association between 
CSF enhancement and hyperlipidemia (Rozanski, 2010)or diabetes 
mellitus (Gupta, 2017). CSF enhancement was not associated with WMH 
in six studies (Freeze, 2017; Rozanski, 2010; Jolink, et al., 2019; Cho, 
2014; Absinta, 2015; Ighani, 2020), but one study in MS reported a 
higher volume of hyperintense lesions in the white matter in cases with 
CSF enhancement compared to cases without CSF enhancement (Zur-
awski, 2020). One study that assessed the relationship between CSF 
enhancement and lacunar infarcts did not find a significant association 
(Freeze, 2017). Of the two studies that assessed the association between 
CSF enhancement and microbleeds, one study did not find an association 
(Freeze, 2017), while another study in cases with ICH reported that 
cases with CSF enhancement more often had lobar cerebral microbleeds 
(13/17, 77%) than those without (5/14, 36%) (Jolink, et al., 2019). In 
contrast, no association was found between CSF enhancement and non- 
lobar microbleeds (Jolink, et al., 2019). Of seven studies that assessed 
associations between CSF enhancement and atrophy, three found no 
association (Freeze, 2017; Absinta, 2017; Zurawski, 2020), while four 
MS studies found positive associations between atrophy and CSF 
enhancement (Absinta, 2015; Bergsland, 2019; Zivadinov, 2017; Ighani, 
2020). 
3.8. Prognostic value 
Two studies in ischemic stroke found that CSF enhancement was 
associated with worse clinical outcome 1–3 months after the event as 
indicated by higher modified Rankin Scales (mRS) in patients with 
compared to those without CSF enhancement (Ostwaldt, 2015; Warach 
and Latour, 2004; Latour et al., 2004). One study of patients with TIA 
found that after 90 days the median mRS was 0 for both cases with and 
without CSF enhancement (Lee, 2015). No information was found on the 
prognostic value of CSF enhancement in other diseases. 
4. Discussion 
CSF enhancement on pcT2wFLAIR images is a frequent finding in 
multiple conditions and diseases, including post-vascular surgery con-
ditions, stroke, and MS, though CSF enhancement can also be found in 
non-neurological controls. Increasing age was identified as a possible 
risk factor for CSF enhancement in multiple studies, while other classical 
vascular risk factors were not. CSF enhancement is associated with ce-
rebral atrophy in patients with MS, and may be associated with cerebral 
amyloid angiopathy in patients with ICH. The clinical and prognostic 
value of CSF enhancement remains unclear. 
We encountered risk of bias within the individual studies, including 
selection bias, presence of confounding factors, and limited power. 
Other factors that might have impacted the frequency estimates 
included failure to acquire pre-contrast FLAIR images in all participants 
and potential unawareness of neuroradiological mimics of GBCA 
enhancement in the CSF space (Stuckey et al., 2007), including 
enhancement in or near dural venous sinuses (Absinta, 2017, 2015; 
Harrison, 2017; Absinta, et al., 2017), basal meninges or large sub-
arachnoid veins (Absinta, 2017, 2015; Harrison, 2017), enhancement 
due to (subarachnoid) hemorrhage (Ostwaldt, 2015; Lee, 2015), or 
hyperoxygenation (Suthiphosuwan et al., 2018). We have attempted to 
minimize the limitations of the individual studies by pooling the results 
of broadly comparable disease groups. At the cross-study level, we 
observed large variations with regard to study samples, MRI sequence 
parameters, contrast agent dosage, and time delay between contrast 
agent administration and pcT2wFLAIR acquisition. Moreover, many 
studies failed to report one or more of these important methodological 
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aspects in detail. The methodological variability between studies is re-
flected by the large heterogeneity in prevalence estimates among studies 
with broadly comparable disease groups. This, together with the 
absence of a common terminology and neuroradiological definition of 
CSF enhancement, makes it challenging to directly compare studies. In 
the literature we found two frequently used terms for CSF enhancement, 
including ‘hyperintense acute reperfusion marker’ (HARM) and ‘lep-
tomeningeal enhancement’ (LME). However, these terms may not be 
universally applicable since it remains unclear whether reperfusion 
constitutes the main mechanism underlying CSF enhancement, and 
enhancement has also been observed in CSF spaces beyond the sub-
arachnoid space. Therefore, we propose using the neutral term ‘cere-
brospinal fluid (CSF) enhancement’. 
The optimal imaging acquisition methodology to capture CSF 
enhancement remains unclear. Because of the large heterogeneity in 
imaging methodology and study samples we did not formally assess 
associations between the prevalence of CSF enhancement and specific 
imaging aspects, though from our experience and extensive review of 
the literature we infer several factors that are likely to influence the 
conspicuity of low GBCA concentrations in the CSF. Firstly, several 
studies have demonstrated that the likelihood and conspicuity of CSF 
enhancement on pcT2wFLAIR images increases with higher contrast 
agent dosage or with multiple doses (Mamourian et al., 2000; Ostwaldt, 
2015, 2014; Kidwell et al., 2011; Wilkinson, 2000). On a related note, 
the rate of GBCA excretion, which is dependent on renal functioning, 
might also affect the appearance of CSF enhancement, especially in 
studies with long post-contrast acquisition delays. Secondly, we recently 
demonstrated that the conspicuity of CSF enhancement due to low GBCA 
concentrations is strongly dependent on the parameters of the 
pcT2wFLAIR sequence, and especially benefits from a longer echo time 
(Freeze, 2019). Thirdly, 2D pcT2wFLAIR sequences are likely insensitive 
for the detection of subtle focal CSF enhancement due to the thicker 
slices compared with 3D sequences with isotropic voxel sizes (Eisele, 
2015). Fourthly, MS studies performed at 7 T found higher frequencies 
of CSF enhancement compared to studies performed at 3 T (Eisele, 2015; 
Absinta, 2015; Coulette, 2019; Harrison, 2017; Jonas et al., 2018; 
Zivadinov, 2017, 2018; Zurawski, 2020; Ighani, 2020), which suggests 
that the magnetic field strength influences the conspicuity of CSF 
enhancement (possibly due to an increased signal-to-noise ratio). 
Fifthly, one study has recently demonstrated the added value of using 
pre- and post-contrast subtraction images for the detection of focal 
pericortical enhancement, as this method avoided false-positives and 
increased the accuracy detecting focal CSF enhancement (Zivadinov, 
2018). Finally, it currently remains unclear what the optimal acquisition 
timing for the detection of CSF enhancement is in different diseases. It is 
important to be aware that post-contrast acquisition timing likely in-
fluences the CSF enhancement appearance, as stroke studies with mul-
tiple acquisition moments showed that absent or focal enhancement can 
transform in widespread diffuse signal enhancement throughout the 
subarachnoid space at later timepoints (Warach and Latour, 2004; 
Latour et al., 2004; Lee, 2015, 2016). Many questions remain as to how 
CSF enhancement appears on differently timed pcFLAIR acquisitions. 
For example, it remains unknown whether focal leakage observed 
within minutes after GBCA administration can transform into diffuse 
CSF enhancement at later timepoints in diseases other than stroke. In 
addition, while studies in MS and memory clinic patients show that CSF 
enhancement can be a chronic phenomenon in these diseases, no studies 
to date have performed follow-up imaging in the chronic phase of 
ischemic stroke. Moreover, it remains unclear whether and how the 
appearance of CSF enhancement in acute stroke (and perhaps also post- 
surgical conditions) is associated with the elapsed time between the 
event and imaging, as post-stroke BBB opening is considered to be a 
dynamic process (Sandoval and Witt, 2008). 
Interestingly, the finding of widespread contrast agent retention in 
the subarachnoid space up to several days after contrast administration 
in multiple studies of stroke cases suggests that CSF enhancement forms 
a potential biomarker for impaired CSF dynamics and/or clearance de-
ficiencies (glymphatics) (Deike-Hofmann, 2019; Lee, 2018), as the 
appearance of CSF enhancement is influenced by a mix of BBB opening 
and CSF washout. The increased sensitivity of pcT2w FLAIR to low 
GBCA concentrations compared with pcT1w imaging, as demonstrated 
by previous studies (Mathews, 1999; Freeze, 2017; Kohrmann et al., 
2012), makes this technique especially suitable for tracking the circu-
lation of GBCA through the various CSF compartments. Previous work 
has demonstrated the feasibility of tracking changes in CSF signal in-
tensity over time in the ventricles, perivascular spaces, and cisterns, 
both in control participants and patients with BBB impairment due to 
cerebral metastases (Deike-Hofmann, 2019). Furthermore, recent 
studies have shown that glymphatic functioning in the form of GBCA 
clearance from the CSF can be investigated with repeated pcT2wFLAIR 
imaging after intrathecal GBCA administration (Ringstad and Eide, 
2020; Ringstad et al., 2017). 
Several studies reported on associations between possible (vascular) 
risk factors and neuroradiological features. Among the examined risk 
factors, higher age stood out as a universal risk factor among neuro-
logical study samples (n = 11/20 studies), which is in line with previous 
studies that found associations between BBB leakage and increasing age 
(Farrall and Wardlaw, 2009). However, none of the included studies 
Box 3 
: Recommendations for future studies. 
Suggested standardized terminology: Cerebrospinal fluid (CSF) enhancement. 
Suggested standardized definition: Signal enhancement within cerebrospinal fluid compartments on T2-weighted FLAIR images after intra-
venous administration of a GBCA; this enhancement may be detected up to several days after GBCA administration. 
Recommended standardized methodology:  
• Acquire pre-contrast FLAIR images in all cases to rule out potential mimics of CSF enhancement (Absinta, 2015; Stuckey et al., 2007).  
• Use a relatively long echo time (e.g. ~ 500 ms at 3 T (Freeze et al., 2019) for increased sensitivity to lower GBCA concentrations in CSF.  
• Use a 3D FLAIR sequence to increase spatial resolution and thus sensitivity to focal CSF hyperintensities (e.g. resolution ≤ 1 mm isotropic).  
• Administer GBCA only once using a standard single dose and maximize safety when choosing a contrast agent type (e.g. use a macrocyclic 
GBCA, exclude cases with renal failure).  
• Standardize timing of pcT2wFLAIR acquisition and, if possible, acquire FLAIR images at multiple time points after contrast administration (e. 
g. standardized after 10 min and repeatedly acquire sequence with intervals of several hours to days) to evaluate the appearance and location 
of CSF enhancement over time.  
• Include an appropriate control sample (e.g. matched on relevant variables such as age, sufficient sample size) to determine the relative 
frequency of CSF enhancement.  
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looked at the association between CSF enhancement and age within non- 
neurological controls so it is possible that the observed associations can 
be explained by increases in disease severity and/or duration with age. 
Nevertheless, age should likely be considered an important confounding 
variable when comparing pooled prevalence estimates, especially be-
tween disease groups and controls. 
None of the included studies reported significant positive associa-
tions between CSF enhancement and sex or vascular risk factors. With 
regard to neuroradiological correlates, one study in post-acute ICH pa-
tients found a positive association between CSF enhancement and the 
presence of lobar cerebral microbleeds (Jolink, et al., 2019), suggesting 
a role for that cerebral amyloid angiopathy in BBB disruption, in line 
with neuropathological observations and other previous studies (Freeze, 
2019, 2018). In addition, one study in MS reported a higher volume of 
white matter hyperintense lesions in cases with CSF enhancement 
compared to those without, and four studies in MS reported increased 
atrophy in cases with compared to cases without CSF enhancement. 
Together, these findings suggest that inflammatory and/or neurode-
generative processes might play an important role in the formation of 
CSF enhancement. This hypothesis is supported by one study that 
showed perivascular inflammation at the location where CSF enhance-
ment was observed during life in two MS patients who came to autopsy 
(Absinta, 2015). We found only three studies that assessed the prog-
nostic value of CSF enhancement over a time course of >1 month, and 
two of these indicated worse clinical performance in ischemic stroke 
cases. 
Future prospective studies should further explore the clinical and 
prognostic significance of CSF enhancement in different disease types 
while including appropriate (age-matched, sufficient sample size, and 
scanned under the same conditions as diseased cases) control samples to 
determine the relative prevalence of CSF enhancement, as well as its 
pathological correlates. Longitudinal studies that assess CSF enhance-
ment over a time course of several hours to days could shed light on the 
dynamics between BBB leakage on the one hand and CSF flow and 
clearance mechanisms on the other hand. The optimal methodological 
parameters to detect subtle GBCA leakage in CSF should be explored at 
different field strengths. Furthermore, future studies should explore 
automated methods to detect CSF enhancement on pcT2wFLAIR images 
for improved visibility and quantification. To facilitate increased quality 
and comparison between studies, we have formulated recommendations 
(box 3) for future studies. 
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